Brazilian researchers have developed a simple test that almost instantly tells whether a person has been exposed to any of ...

The European Investment Bank (EIB) has signed a €20 million loan agreement with Universal DX, a Spanish startup pioneering blood-based liquid b ...

Diagnosing ALS is a challenge, but new research has found a highly effective way to detect and track the disease using blood ...

During a live event, participating oncologists discuss the role of ctDNA and molecular testing in muscle-invasive bladder ...

Trichomoniasis is one of the most common sexually transmitted infections in the world. It is caused by Trichomonas vaginalis, ...

Great Southern Copper plc has reported exceptional first assay results from Phase 1 drilling at the Mostaza mine, Cerro Negro ...

A new assay rapidly detected pancreatic ductal adenocarcinoma and differentiated it from noncancer pancreatic diseases by ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of Labcorp® Plasma CompleteTM, a circulating tumor DNA (ctDNA)-based ...

The PAC-MANN test was able to differentiate — 98% of the time — between the blood of someone with pancreatic cancer and the ...

Paired with an existing test, this could become a life-saving diagnostic tool for people with a notoriously deadly form of ...

The study developed a noninvasive detection method based on serum protease activity, leveraging the increased protease activity in the peripheral blood of patients with PDAC. Researchers screened a ...

As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.